Loading
A phase 2 trial in lung cancer, run by Tubulis GmbH, not yet recruiting.
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT07806773 by Tubulis GmbH, with a registry enrolment figure of 80 participants, started 2026-11 and due to reach its primary completion in 2029-05. Interventions recorded: TUB-040. Conditions listed: NSCLC; Non Small Cell Lung Cancer. Primary outcome: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs); Overall Response Rate (ORR). Lung eligibility wording from the registry: "Mixed histology NSCLC (eg, small cell lung cancer/NSCLC) or histology other than adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.